

**Preliminary Results of Public Joint Shareholders Company
(Final Result Brief for the year ended 31/12/2020)**

First - General Information:

Name of the company:	Gulf Pharmaceutical Industries (JULPHAR)
Date Establishment:	1980
Paid up capital:	1,155,227,811
Subscribed capital:	1,155,227,811
Authorized capital:	1,155,227,811
Chairman of the Board:	Sh. Saqr Bin Humaid Al Qasimi
Chief Executive Officer:	Dr. Essam Mohamed Farouk
Name of the external auditor:	M/S. Ernst & Young
Mailing address:	P.O.Box: 997
Tel:	009717 2461461
Fax:	0097172462462
E – mail:	julphar@emirates.net.ae



Second - Preliminary Results (000 AED) :


	2020	2019
Total Assets	2,334,300	2,450,400
Shareholders' Equity	1,069,000	878,000
Revenues	581,800	301,500
EBITDA from Operations before one-time effects	1,500	-268,300
Net Operating Loss before one-time effects	-89,300	-356,200
One-time effects	-191,800	-122,900
Net Operating Loss before Tax & Finance Cost	-281,100	-479,100
Net loss for the period after Tax & Finance Cost	-315,400	-518,900
Earnings per share (In UAE fils)	-27.2	-43.1

7-Summary of the company's performance for the last fiscal year.

Julphar recorded net revenues of 581.8 mAED for the year 2020, an increase of 93% from previous year. The strong revenue growth is driven by the relaunch of its operations in the export markets of KSA, Oman, Kuwait & Bahrain after the successful reinspection of its production facilities by the Saudi Arabia and GCC health authorities in January 2020. The Group successfully improved the operational performance in 2020 and recorded a 1.5 mAED positive EBITDA from Operations before one-time effects. The net loss of the Group reduced from -518.9 mAED in 2019 to -315.4 mAED in 2020. (It includes 191.8 mAED for asset write downs and other one-time effects). The Group continues to divest from its non-core assets to focus on core areas of the business.

The management has made substantial progress in the implementation of the transformation agenda during 2020. In addition, it has successfully restructured the registered capital base which will allow the Group to follow through new growth initiatives in its product portfolio and new business initiatives in the coming years.

Julphar is committed to providing the most affordable and highest quality health care solutions in the MENA region.

The name of the chairman of the company or the authorized signatory	
Signature and Date	
Company's Seal	14/02/2021

